Monoclonal Antibodies (MAbS) Global Market Report 2023
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- Major players in the monoclonal antibodies (MABS) market are Johnson & Johnson, Merck,…
152,880€
1,08%
Echtzeit-Aktienkurs ABBVIE
Bid:
Ask:
Nachrichten zur ABBVIE Aktie
Monday’s Top Analyst Upgrades and Downgrades: AbbVie, Affirm, Lyft, Micron Technology, Tapestry, Walmart, Western Digital and More
Mondays top analyst upgrades and downgrades included AbbVie, Affirm, Bloom Energy, FREYR Battery, International Flavors & Fragrances, Interpublic Group of…
AbbVie, Ironwood Linzess gets FDA priority review to treat functional constipation in children
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Anesthesia Drugs Market to Grow by USD 1.38 Bn, AbbVie Inc. and Baxter International Inc. Among Key Vendors - Technavio
NEW YORK, Feb. 12, 2023 /PRNewswire/ -- The Anesthesia Drugs Market by Type, Route of Administration, and Geography - Forecast…
AbbVie (ABBV) Q4 2022 Earnings Call Transcript
ABBV earnings call for the period ending December 31, 2022....…
AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales
AbbVies Q4 earnings (ABBV) beat estimates, while sales miss the same. Full-year 2023 EPS falls short of estimates....…
AbbVie gains after revising estimates for Humira sales erosion
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Outlook Falls Short of Estimates as Humira Faces Biosimilar ...
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie (ABBV) Q4 Earnings Beat Estimates
AbbVie (ABBV) delivered earnings and revenue surprises of 1.69% and 1.52%, respectively, for the quarter ended December 2022. Do the…
AbbVie: Solide Zahlen - Aktienanalyse
Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG:
Benedikt-Luka Antic, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…
AbbVie Posts an Earnings Beat but Forecast Misses as Competition Intensifies
AbbVie says international sales of Humira in the fourth quarter fell 26.5% from a year earlier....…
AbbVie sets outlook below consensus amid generic threat to best selling drug
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie’s stock gains on Q4 results
Shares of AbbVie Inc. ABBV gained 2.4% in premarket trading on Thursday after the company beat earnings expectations for the…
Form 8-K AbbVie Inc. For: Feb 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent; Adjusted Diluted EPS of $13.77,…
AbbVie Non-GAAP EPS of $3.60 beats by $0.02, revenue of $15.12B misses by $180M, initiates FY outlook
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Q4 results in focus with eye on new drugs as Humira challengers enter US doors
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Earnings Previews: AbbVie, Cameco, Canopy Growth, PepsiCo, Under Armour
Before U.S. markets open on Thursday, AbbVie, Cameco, Canopy Growth, PepsiCo and Under Armour will report quarterly earnings....…
Teva follows AbbVie to leave top pharma industry group
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie pins hopes on newer drugs and deals to face Humira knockoffs – WSJ
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira
Drugmaker is turning to next-generation successors to Humira to replenish billions of dollars in sales that will be lost, and…
Zulassung von Medikamenten: Wie ein Pharmakonzern den Patentschutz bis zum Letzten ausreizt
Abbvie hat den Schutz für seinen Bestseller Humira jahrelang künstlich in die Länge gezogen und Milliarden damit verdient. Auch wegen…
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could…
AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
AbbVie (ABBV) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Insights on the Facial Aesthetics Global Market to 2028 - Featuring AbbVie, Merz Pharma, Galderma and Candela Medical Among Others
DUBLIN, Jan. 31, 2023 /PRNewswire/ -- The "Global Facial Aesthetics Market Size, Share & Industry Trends Analysis Report By Product…
AbbVie (ABBV) Stock Moves -0.43%: What You Should Know
AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day....…
Insights on the HIV/AIDS Diagnostics Global Market to 2030 - Featuring Abbott Laboratories, Abbvie, Alere, Apogee Flow Systems and Beckman Coulter Among Others
DUBLIN, Jan. 30, 2023 /PRNewswire/ -- The "HIV/AIDS Diagnostics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key…
Emergency contraceptive pills market to grow by 3.72% Y-O-Y from 2022 to 2023: Rise in the number of initiatives to create awareness will drive growth -Technavio
NEW YORK, Jan. 30, 2023 /PRNewswire/ -- Emergency contraceptive pills market insights - Vendors: 15+, Including AbbVie Inc. | Afaxys…
How a Drug Company Made $114 Billion by Gaming the U.S. Patent System
AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is…
Lipid Based Formulations Global Market Report 2023: Featuring Novartis, AbbVie, F. Hoffmann-La Roche, Johnson & Johnson, Alnylam Pharmaceuticals & More
DUBLIN, Jan. 27, 2023 /PRNewswire/ -- The "Lipid Based Formulations Market - Global Industry Size, Share, Trends, Opportunity and Forecast,…
Global Psoriasis Therapeutics Market Report to 2031 - Featuring Abbvie, Amgen, Bausch Health, LEO Pharma and Novan Among Others
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "Psoriasis Therapeutics Market By Drug Class, By Type, By Route of Administration: Global…
3 Reasons to Buy AbbVie and 2 Reasons Not to Buy
The pharmaceutical specialist is facing a pivotal year in 2023, thanks to growing competition....…
China Anti-Rheumatic Drug Markets Report 2022-2027 Featuring Pfizer, F. Hoffmann-La Roche, UCB S.A., Eli Lilly and Company, & AbbVie Inc.
DUBLIN, Jan. 24, 2023 /PRNewswire/ -- The "China Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027" report has been…
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, AbbVie (ABBV) closed at $148.55, marking a -0.7% move from the previous day....…
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what…
Final Trades: Abbvie, Goldman Sachs, Charles River & more
The "Halftime Report" traders give their top picks to watch for the second half....…
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
In the latest trading session, AbbVie (ABBV) closed at $152.83, marking a -0.5% move from the previous day....…
Übernahme von Botox-Hersteller gibt AbbVie Schub
Frankfurt (Reuters) - Der US-Pharmakonzern AbbVie profitiert von einer hohen Nachfrage nach seinem Blockbuster-Medikament Humira und der Übernahme des Botox-Herstellers…
Agentur - Boehringer und AbbVie in Gesprächen über Krebs-Allianz
Bangalore (Reuters) - Deutschlands zweitgrößter Pharmakonzern Boehringer Ingelheim steht einem Agenturbericht zufolge vor einer umfassenden Partnerschaft bei Krebs-Therapien mit dem…